MetaVia announce late-breaking abstract for DA-1726 for the treatment of obesity at EASL 2026 Congress
MetaVia announced that a late-breaking abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27–30, 2026 in Barcelona, Spain.
“Having a late-breaking abstract on DA-1726 accepted for a poster presentation at the prestigious EASL Congress underscores the strength of this asset,” stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. “DA-1726 continues to demonstrate potential for a differentiated, best-in-class profile and is currently being evaluated in a 16-week Phase 1 Part 3 titration study designed to optimize higher dose levels and tolerability, with data expected in the fourth quarter of this year.”
- Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with Exploratory Noninvasive Liver Assessment
- Presenting Author: Chris Fang, Chief Medical Officer, MetaVia
- Abstract Number: LB26-5204
- Final Abstract ID: LBP-010
- Session: Late Breaking Posters
- Presentation Date: Wednesday, May 27, 2026
- Presentation Start: 8:30 am CET
A copy of the poster will be available on the Posters section of the MetaVia website after the presentation.
